FGP
MAZE

Freestone Grove Partners’s Maze Therapeutics MAZE Stock Holding History

Freestone Grove Partners’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.01M Buy
234,953
+116,077
+98% +$5.12M 0.05% 308
2025
Q4 		$4.93M Buy
+118,876
New +$4.09M 0.04% 349

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Freestone Grove Partners's MAZE Position: Q1 2026 in Review

Freestone Grove Partners increased its Maze Therapeutics (MAZE) stake by 98% in Q1 2026, buying an estimated $5.12M and bringing the position to 234,953 shares worth $7.01M. The position accounts for 0.05% of the portfolio, ranked #308.

Freestone Grove Partners first reported a position in MAZE in Q4 2025 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Freestone Grove Partners held 234,953 shares of Maze Therapeutics worth $7.01M as of Q1 2026.
  • Freestone Grove Partners bought 116,077 Maze Therapeutics shares in Q1 2026, an estimated $5.12M.
  • Maze Therapeutics made up 0.05% of Freestone Grove Partners's portfolio in Q1 2026, its #308 holding.
  • Freestone Grove Partners first reported a position in Maze Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.